Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
A Phase 1/1b Trial of MRTX849 in Combination With Palbociclib in Patients With Advanced Solid Tumors With KRAS G12C Mutation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Expanded Access
Expanded Access
Approved
- Available: Expanded access is currently available for this investigational treatment, and patients who are not participants in the clinical study may be able to gain access to the drug, biologic, or medical device being studied.
- No longer available: Expanded access was available for this intervention previously but is not currently available and will not be available in the future.
- Temporarily not available: Expanded access is not currently available for this intervention but is expected to be available in the future.
- Approved for marketing: The intervention has been approved by the U.S. Food and Drug Administration for use by the public.
Contacts and Locations
Study Locations
-
-
Florida
-
Orlando, Florida, United States, 32827
- Local Institution - 804
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Local Institution - 803
-
-
Texas
-
Houston, Texas, United States, 77030
- Local Institution - 802
-
San Antonio, Texas, United States, 78229
- Local Institution - 801
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
- Unresectable or metastatic disease.
- No available treatment with curative intent
- Adequate organ function
Exclusion Criteria:
- History of significant toxicity on prior KRAS G12C or CDK4/6 inhibitor therapies
- History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter the absorption of study treatment or result in an inability to swallow
- Other active cancer
- Cardiac abnormalities
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dose Escalation
Dose escalation of MRTX849 and palbociclib to determine maximum tolerated dose in combination.
|
KRAS G12C inhibitor
Other Names:
CDK 4 and 6 inhibitor
Other Names:
|
|
Experimental: Dose Expansion
Expansion cohorts may be implemented to ensure sufficient safety experience, pharmacokinetic data and early evidence of clinical activity of MRTX in combination with palbociclib.
|
KRAS G12C inhibitor
Other Names:
CDK 4 and 6 inhibitor
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Characterize the number of patients with treatment emergent adverse events of the combination regimen in patients with advanced solid tumor malignancies with KRAS G12C mutation.
Time Frame: 24 months
|
Number of participants with treatment emergent adverse events
|
24 months
|
|
Evaluate Pharmacokinetics of the combination regimen
Time Frame: 24 months
|
Plasma concentration
|
24 months
|
|
Establish Maximum Tolerated Dose
Time Frame: 24 months
|
Number of patients with dose limiting toxicity
|
24 months
|
|
Evaluate preliminary clinical activity of the combination regimen
Time Frame: 24 months
|
Objective response rate in accordance with Response Evaluation Criteria in Solid Tumors (RECIST)
|
24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CA239-0018 (Other Identifier: Bristol-Myers Squibb Protocol ID)
- 849-016 (Other Identifier: Mirati Therapeutics Protocol ID)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.